Phase 1 First-in Human randomized, open-label, active control standard of care study of the
safety of HBN-1 administered as pharmacologically induced hypothermia as an adjunct to
standard of care targeted temperature management in adult patients who have experienced
out-of-hospital-cardiac arrest. HBN-1 will be administered IV as a loading dose infusion
followed by a 12-hour maintenance infusion.